Follicular Lymphoma And Marginal Zone Lymphoma clinical trials

Explore recruiting follicular lymphoma and marginal zone lymphoma clinical trials.

Recruiting follicular lymphoma and marginal zone lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Follicular Lymphoma And Marginal Zone Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Spain, Czechia, Poland, Austria, Germany, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Follicular Lymphoma And Marginal Zone Lymphoma trials by city

Follicular Lymphoma And Marginal Zone Lymphoma clinical trials

Recruiting follicular lymphoma and marginal zone lymphoma studies right now

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Study of ARC-02 in B-cell NHL

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Also recruiting in Europe

Follicular Lymphoma And Marginal Zone Lymphoma trials by city

Other conditions